FGFR4 (N535K)
Sign in to save this workspaceFGFR4 · Variant type: point · HGVS: p.N535K
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ponatinib | 94.6% | 5.4% | 78.23 |
| 2 | Erdafitinib | 83.2% | 16.8% | 95.71 |
| 3 | Selpercatinib | 80.8% | 19.2% | 96.72 |
| 4 | Canertinib | 72.7% | 27.3% | 96.49 |
| 5 | Lenvatinib | 72.5% | 27.5% | 97.74 |
| 6 | Brigatinib | 51.0% | 49.0% | 82.96 |
| 7 | Vandetanib | 49.3% | 50.7% | 95.74 |
| 8 | Alectinib | 45.9% | 54.1% | 95.49 |
| 9 | Futibatinib | 43.3% | 56.7% | 98.48 |
| 10 | Pemigatinib | 33.4% | 66.6% | 98.23 |
| 11 | Tivozanib | 30.9% | 69.1% | 92.42 |
| 12 | Infigratinib | 24.7% | 75.3% | 98.24 |
| 13 | Tenalisib | 19.5% | 80.5% | 97.98 |
| 14 | Alpelisib | 17.1% | 82.9% | 97.22 |
| 15 | Selumetinib | 16.0% | 84.0% | 100.00 |
| 16 | Imatinib | 14.9% | 85.1% | 99.00 |
| 17 | Lazertinib | 12.9% | 87.1% | 97.47 |
| 18 | Apatinib | 12.5% | 87.5% | 97.73 |
| 19 | Gedatolisib | 11.7% | 88.3% | 99.75 |
| 20 | Ribociclib | 11.3% | 88.7% | 99.25 |
| 21 | Everolimus | 11.1% | 88.9% | 100.00 |
| 22 | Pralsetinib | 11.0% | 89.0% | 93.43 |
| 23 | Cabozantinib | 11.0% | 89.0% | 92.73 |
| 24 | Temsirolimus | 10.0% | 90.0% | 100.00 |
| 25 | Umbralisib | 9.5% | 90.5% | 98.74 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ponatinib | 94.6% | 96.7% | -2.1% |
| Erdafitinib | 83.2% | 98.0% | -14.8% |
| Selpercatinib | 80.8% | 49.1% | +31.6% |
| Canertinib | 72.7% | — | — |
| Lenvatinib | 72.5% | 79.3% | -6.7% |
| Brigatinib | 51.0% | 73.3% | -22.3% |
| Vandetanib | 49.3% | — | — |
| Alectinib | 45.9% | 36.3% | +9.6% |
| Futibatinib | 43.3% | 97.9% | -54.6% |
| Pemigatinib | 33.4% | 93.9% | -60.5% |
| Tivozanib | 30.9% | 37.5% | -6.6% |
| Infigratinib | 24.7% | 94.7% | -70.0% |
| Tenalisib | 19.5% | 83.9% | -64.4% |
| Alpelisib | 17.1% | 96.8% | -79.7% |
| Selumetinib | 16.0% | — | — |
| Imatinib | 14.9% | — | — |
| Lazertinib | 12.9% | — | — |
| Apatinib | 12.5% | — | — |
| Gedatolisib | 11.7% | — | — |
| Ribociclib | 11.3% | — | — |
| Everolimus | 11.1% | — | — |
| Pralsetinib | 11.0% | 64.6% | -53.6% |
| Cabozantinib | 11.0% | — | — |
| Temsirolimus | 10.0% | — | — |
| Umbralisib | 9.5% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_breast | Breast | ref |
| carcinoma_pancreas | Pancreas | ref |
| rhabdomyosarcoma_soft_tissue | Soft Tissue | ref |
| carcinoma_large_intestine | Large Intestine | ref |
| carcinoma_liver | Liver | ref |
| sex_cord-stromal_tumour_testis | Genitourinary system | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 30.5ms